- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances in vascular disrupting agents in cancer therapy
Authors
Keywords
-
Journal
Future Medicinal Chemistry
Volume 6, Issue 13, Pages 1485-1498
Publisher
Future Science, LTD
Online
2014-11-03
DOI
10.4155/fmc.14.104
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)
- (2014) Marc C. Chamberlain et al. JOURNAL OF NEURO-ONCOLOGY
- Arsenic Trioxide as a Vascular Disrupting Agent: Synergistic Effect with Irinotecan on Tumor Growth Delay in a CT26 Allograft Model
- (2014) Jong Cheo Lee et al. Translational Oncology
- TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis
- (2013) Elena Porcù et al. ANGIOGENESIS
- Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
- (2013) S M Tijono et al. BRITISH JOURNAL OF CANCER
- Anti-angiogenesis in cancer therapy: Hercules and hydra
- (2013) S. Bellou et al. CANCER LETTERS
- Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors
- (2013) C. Sessa et al. CLINICAL CANCER RESEARCH
- Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers
- (2013) Harish Rajak et al. CURRENT PHARMACEUTICAL DESIGN
- VE-Cadherin and Endothelial Adherens Junctions: Active Guardians of Vascular Integrity
- (2013) Monica Giannotta et al. DEVELOPMENTAL CELL
- Synthesis and Biological Evaluation of 2-(Alkoxycarbonyl)-3-Anilinobenzo[b]thiophenes and Thieno[2,3-b]pyridines as New Potent Anticancer Agents
- (2013) Romeo Romagnoli et al. JOURNAL OF MEDICINAL CHEMISTRY
- Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme
- (2013) Yasushi Soda et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development
- (2013) Federico Innocenti et al. Pharmacogenetics and Genomics
- KML001 Displays Vascular Disrupting Properties and Irinotecan Combined Antitumor Activities in a Murine Tumor Model
- (2013) Chang Hoon Moon et al. PLoS One
- D Quantification of Tumor Vasculature in Lymphoma Xenografts in NOD/SCID Mice Allows to Detect Differences among Vascular-Targeted Therapies
- (2013) Marco Righi et al. PLoS One
- Tumor Delivery of Chemotherapy Combined with Inhibitors of Angiogenesis and Vascular Targeting Agents
- (2013) Marta Cesca et al. Frontiers in Oncology
- The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts
- (2012) Dušan Milanović et al. BMC CANCER
- Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer
- (2012) P. Nathan et al. CLINICAL CANCER RESEARCH
- Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors
- (2012) Dan M. Patterson et al. CLINICAL CANCER RESEARCH
- Combination of vascular disrupting agents and ionizing radiation
- (2012) Céline Clémenson et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Vascular disrupting agents
- (2012) Antoine Hollebecque et al. CURRENT OPINION IN ONCOLOGY
- Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent
- (2012) Matthew Burge et al. INVESTIGATIONAL NEW DRUGS
- The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models
- (2012) Céline Clémenson et al. INVESTIGATIONAL NEW DRUGS
- Modulation of Chemotherapeutic Efficacy by Vascular Disrupting Agents: Optimizing the Sequence and Schedule
- (2012) Eunice S. Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Vascular Disrupting Agent Drug Classes Differ in Effects on the Cytoskeleton
- (2012) Sujeong Kim et al. PLoS One
- Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft
- (2011) Xian-hua Fu et al. CANCER LETTERS
- Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation
- (2011) D. Rischin et al. CLINICAL CANCER RESEARCH
- Preclinical Efficacy of Vascular Disrupting Agents in Non–Small-Cell Lung Cancer
- (2011) Bruce C. Baguley Clinical Lung Cancer
- Classification and Toxicities of Vascular Disrupting Agents
- (2011) Arman Hasani et al. Clinical Lung Cancer
- Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel
- (2011) Michael Millward et al. INVESTIGATIONAL NEW DRUGS
- Clinical Development of Vascular Disrupting Agents: What Lessons Can We Learn From ASA404?
- (2011) Patricia M. LoRusso et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties
- (2011) Bernard L. Flynn et al. JOURNAL OF MEDICINAL CHEMISTRY
- Convergent Synthesis and Biological Evaluation of 2-Amino-4-(3′,4′,5′-trimethoxyphenyl)-5-aryl Thiazoles as Microtubule Targeting Agents
- (2011) Romeo Romagnoli et al. JOURNAL OF MEDICINAL CHEMISTRY
- Regioselective Suzuki Coupling of Dihaloheteroaromatic Compounds as a Rapid Strategy To Synthesize Potent Rigid Combretastatin Analogues
- (2011) Sewan Theeramunkong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis and Evaluation of 1,5-Disubstituted Tetrazoles as Rigid Analogues of Combretastatin A-4 with Potent Antiproliferative and Antitumor Activity
- (2011) Romeo Romagnoli et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Microtubule Depolymerizing Agent CYT997 Causes Extensive Ablation of Tumor Vasculature In Vivo
- (2011) C. J. Burns et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Vascular Disruption in Combination with mTOR Inhibition in Renal Cell Carcinoma
- (2011) L. Ellis et al. MOLECULAR CANCER THERAPEUTICS
- Aminolevulinic Acid-Photodynamic Therapy Combined with Topically Applied Vascular Disrupting Agent Vadimezan Leads to Enhanced Antitumor Responses
- (2011) Allison Marrero et al. PHOTOCHEMISTRY AND PHOTOBIOLOGY
- Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis
- (2010) Xiaofeng Zhao et al. ADVANCED DRUG DELIVERY REVIEWS
- Biological evaluation of KRIBB3 analogs as a microtubule polymerization inhibitor
- (2010) Sangku Lee et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Adherens junctions connect stress fibers between adjacent endothelial cells
- (2010) Jaime Millan et al. BMC BIOLOGY
- Angiogenesis Inhibitors: Current Strategies and Future Prospects
- (2010) K. M. Cook et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Disrupting established tumor blood vessels
- (2010) Mark J. McKeage et al. CANCER
- The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents
- (2010) Dietmar W. Siemann CANCER TREATMENT REVIEWS
- Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC
- (2010) R. Pili et al. CLINICAL CANCER RESEARCH
- Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
- (2010) Amir Abdollahi et al. DRUG RESISTANCE UPDATES
- Temporal aspects of the action of ASA404 (vadimezan; DMXAA)
- (2010) Bruce C Baguley et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies
- (2010) Chryso Kanthou et al. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
- Synthesis and Antitumor Activity of 1,5-Disubstituted 1,2,4-Triazoles as Cis-Restricted Combretastatin Analogues
- (2010) Romeo Romagnoli et al. JOURNAL OF MEDICINAL CHEMISTRY
- BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy
- (2010) G. Kremmidiotis et al. MOLECULAR CANCER THERAPEUTICS
- Phase I Clinical Trial of MPC-6827 (Azixa), a Microtubule Destabilizing Agent, in Patients with Advanced Cancer
- (2010) A.-M. Tsimberidou et al. MOLECULAR CANCER THERAPEUTICS
- Antivascular Actions of Microtubule-Binding Drugs
- (2009) E. L. Schwartz CLINICAL CANCER RESEARCH
- Preclinical evaluation of vascular-disrupting agents in Ewing’s sarcoma family of tumours
- (2009) Surita Dalal et al. EUROPEAN JOURNAL OF CANCER
- Angiogenesis in pre-malignant conditions
- (2009) Marius Raica et al. EUROPEAN JOURNAL OF CANCER
- Anticancer strategies involving the vasculature
- (2009) Victoria L. Heath et al. Nature Reviews Clinical Oncology
- The angiogenic switch in carcinogenesis
- (2009) Vanessa Baeriswyl et al. SEMINARS IN CANCER BIOLOGY
- Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
- (2008) M J McKeage et al. BRITISH JOURNAL OF CANCER
- Tumour vascular disrupting agents: combating treatment resistance
- (2008) G M Tozer et al. BRITISH JOURNAL OF RADIOLOGY
- Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
- (2008) Patricia M. LoRusso et al. INVESTIGATIONAL NEW DRUGS
- Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites
- (2008) S. Honore et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More